The American Journal of Medicine
Volume 120, Issue 3, Supplement 1 , Pages S12-S18 , March 2007

Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus

  • Daniel J. Rader, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Daniel J. Rader, MD, University of Pennsylvania School of Medicine, 654 Biomedical Research Building II/III, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104.

References 

  1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79
  2. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–1200
  3. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  4. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C Conference Participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition [NHLBI/AHA Conference Proceedings]. Circulation. 2004;109:433–438
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  6. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA. 1990;263:2893–2898
  7. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713–718
  8. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clinical Diabetes. 2003;21:186–187
  9. Tchernof A, Lamarche B, Prud’homme D. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care. 1996;19:629–637
  10. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B–25B
  11. Meigs JB, D’Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham offspring study. Diabetes. 1997;46:1594–1600
  12. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A. 1991;88:9959–9963
  13. Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998;273:8225–8231
  14. Brown N, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336–349
  15. Centers for Disease Control and Prevention, Publications and Products. National Diabetes Fact Sheet (General information and national estimates on diabetes in the United States). 2005;Available at: http://www.cdc.gov/diabetes/pubs/factsheet05.htm.
  16. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617–621
  17. Alexander CM, Landsman PB, Teutsch SM, Haffner SM Third National Health and Nutrition Examination Survey (NHANES III) and the National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210–1214
  18. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JF. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–1134
  19. Hanley AJG, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25:1177–1184
  20. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  21. Alberti KG, Zimmet PZ WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications (Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation). Diabet Med. 1998;15:539–553
  22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  23. Bierman EL. George Lyman Duff Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb. 1992;12:647–656
  24. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(suppl 1):S10–S16
  25. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4–S36
  26. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350
  27. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  28. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–544

PII: S0002-9343(07)00033-2

doi: 10.1016/j.amjmed.2007.01.003

The American Journal of Medicine
Volume 120, Issue 3, Supplement 1 , Pages S12-S18 , March 2007

Article Tools

* Image Usage & Resolution